• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 7, Issue 11
  3. Author

Online ISSN: 2515-8260

Volume7, Issue11

In-vivo & In-vitro antioxidant Studies of Telmisortan Used in the Management of Hypertension and Diabetes Mellitus

    Harit Rawal, Dr. Rakesh Patel

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 11, Pages 8461-8473

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Telmisartan is an angiotensin II type 1 receptor blocker and partial agonist of peroxisome proliferator-activated receptor gamma. Here, we investigated the protective capacity of telmisartan against high glucose (HG) elicited oxidative. The activity of lactate dehydrogenase (LDH), NADPH oxidase (NOX), superoxide dismutase (SOD), catalase (CAT) as well as the levels of malondialdehyde (MDA), glutathione (GSH), intracellular reactive oxygen species (ROS), and all other in-vitro & in-vivo antioxidant experimental models. Moreover, the direct antioxidant effect of telmisartan was determined by 2,2-azinobis-(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) assay and protein expression. Telmisartan exhibited antioxidant activity inthe ABTS assay with the IC50 value of 37.5 µM. Additionally, the cell viability, GSH level, SOD and CAT activity were notably elevated by telmisartan. These findings suggest that telmisartan has protective effects on Management of Hypertension and Diabetes Mellitus.
Keywords:
  • PDF (289 K)
  • XML
(2021). In-vivo & In-vitro antioxidant Studies of Telmisortan Used in the Management of Hypertension and Diabetes Mellitus. European Journal of Molecular & Clinical Medicine, 7(11), 8461-8473.
Harit Rawal, Dr. Rakesh Patel. "In-vivo & In-vitro antioxidant Studies of Telmisortan Used in the Management of Hypertension and Diabetes Mellitus". European Journal of Molecular & Clinical Medicine, 7, 11, 2021, 8461-8473.
(2021). 'In-vivo & In-vitro antioxidant Studies of Telmisortan Used in the Management of Hypertension and Diabetes Mellitus', European Journal of Molecular & Clinical Medicine, 7(11), pp. 8461-8473.
In-vivo & In-vitro antioxidant Studies of Telmisortan Used in the Management of Hypertension and Diabetes Mellitus. European Journal of Molecular & Clinical Medicine, 2021; 7(11): 8461-8473.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 54
  • PDF Download: 87
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus